Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens SMAD family member 3 (SMAD3), transcript variant 1
Synonyms:
HSPC193; HsT17436; JV15-2; LDS1C; LDS3; MADH3
Immunogen
A synthetic phospho-specific peptide corresponding to residues surrounding Ser423 and Ser425 of human Smad3 was used as an immunogen. The antibody only detects Smad3 phosphorylated on Serine 423 and Serine 425.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Smad proteins belong to a group of intracellular signal transducers and downstream effectors of TGF-ß/BMP Signaling. The family consists of nine members that are highly conserved in the N- and C-terminal regions (1). Smad3 is a key component in intracellular signaling of transforming growth factor beta (TGF-ß), an inhibitor for tumor cell proliferation (2). Smad3 is activated by activin/TGF-ß receptors, which form a heteromeric complex with Smad4, translocating to the nucleus and regulating the expression of TGF- ß target genes. Interaction of Smad3 with Akt, can initiate TGF- ß induced apoptosis and cell cycle arrest (3). Smad3 expression may be critical in tumor suppression in early stages of gastric carcinogenesis
Related Pathway
Adherens junction
Adipogenesis
Cell cycle
Delta-Notch Signaling Pathway
EGFR1 Signaling Pathway
TGF Beta Signaling Pathway
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on HL-60 cell lysates using anti-Phospho-Smad3 (pS423/425), 1:2000 dilution. Cells were either (A) untreated (B) treated with TGF.
